Cargando…

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival

Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and guide next-line therapy in ALK(+) non-small-cell lung cancer (NSCLC), but the clinical significance of other rebiopsy findings remains unclear. We analysed all stage-IV ALK(+) NSCLC patients with longitudinally assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christopoulos, Petros, Dietz, Steffen, Kirchner, Martina, Volckmar, Anna-Lena, Endris, Volker, Neumann, Olaf, Ogrodnik, Simon, Heussel, Claus-Peter, Herth, Felix J., Eichhorn, Martin, Meister, Michael, Budczies, Jan, Allgäuer, Michael, Leichsenring, Jonas, Zemojtel, Tomasz, Bischoff, Helge, Schirmacher, Peter, Thomas, Michael, Sültmann, Holger, Stenzinger, Albrecht
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356563/ https://www.ncbi.nlm.nih.gov/pubmed/30669647 http://dx.doi.org/10.3390/cancers11010124

Ejemplares similares

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report
por: Volckmar, Anna-Lena, et al.
Publicado: (2016)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
por: Kirchner, Martina, et al.
Publicado: (2019)

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma
por: Kazdal, Daniel, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
por: Neumann, Olaf, et al.
Publicado: (2022)

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
por: Blasi, Miriam, et al.
Publicado: (2022)

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
por: Romanovsky, Eva, et al.
Publicado: (2023)

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
por: Budczies, Jan, et al.
Publicado: (2022)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
por: Rempel, E., et al.
Publicado: (2022)

Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie
por: Kahles, Andy, et al.
Publicado: (2023)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
por: Angeles, Arlou Kristina, et al.
Publicado: (2023)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

Rebiopsy rate after transperineal or transrectal prostate biopsy
por: Marenco Jimenez, Jose L., et al.
Publicado: (2021)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
por: Budczies, Jan, et al.
Publicado: (2018)

Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients
por: Kosmidis, Christoforos, et al.
Publicado: (2019)

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer
por: El Shafie, R.A., et al.
Publicado: (2021)

The characteristics and spatial distributions of initially missed and rebiopsy-detected prostate cancers
por: You, Myung-Won, et al.
Publicado: (2016)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k9fbkmtp2m8bmr6vvceifa1na7